Literature DB >> 12562666

Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene.

A B P van Kuilenburg, J W Baars, R Meinsma, A H van Gennip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12562666     DOI： 10.1093/annonc/mdg056

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  10 in total

1.  Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.

Authors:  Hélène Mounier-Boutoille; Michèle Boisdron-Celle; Estelle Cauchin; Jean-Paul Galmiche; Alain Morel; Erick Gamelin; Tamara Matysiak-Budnik
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

2.  Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.

Authors:  Jin Ho Baek; Jong Gwang Kim; Shi Nae Kim; Dong Hwan Kim; Sang Kyun Sohn; Young Jun Hong; Kyu Bo Lee
Journal:  Korean J Intern Med       Date:  2006-03       Impact factor: 2.884

Review 3.  Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Authors:  Tessa M Bosch; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  How may anticancer chemotherapy with fluorouracil be individualised?

Authors:  Su-arpa Ploylearmsaeng; Uwe Fuhr; Alexander Jetter
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population.

Authors:  Mohammad Hadi Abbasian; Nafiseh Ansarinejad; Bahareh Abbasi; Masoud Iravani; Tayeb Ramim; Fahime Hamedi; Ali M Ardekani
Journal:  Avicenna J Med Biotechnol       Date:  2020 Jul-Sep

6.  Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.

Authors:  Steven M Offer; Croix C Fossum; Natalie J Wegner; Alexander J Stuflesser; Gabriel L Butterfield; Robert B Diasio
Journal:  Cancer Res       Date:  2014-03-19       Impact factor: 12.701

7.  Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results.

Authors:  J Robert O'Neill; Ewan D Kennedy; Vicki Save; Barbara Langdale-Brown; Lucy Wall; Richard J E Skipworth; Simon Paterson-Brown
Journal:  Int J Surg Oncol (N Y)       Date:  2017-01-13

Review 8.  Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy.

Authors:  Robert B Diasio; Steven M Offer
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

9.  High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.

Authors:  Emma Borràs; Emma Dotor; Angels Arcusa; Maria J Gamundi; Imma Hernan; Miguel de Sousa Dias; Begoña Mañé; José A G Agúndez; Miguel Blanca; Miguel Carballo
Journal:  Front Genet       Date:  2013-01-17       Impact factor: 4.599

10.  Life-Threatening Reaction with Topical 5-Fluorouracil.

Authors:  Patrick Kishi; Cynthia J Price
Journal:  Drug Saf Case Rep       Date:  2018-01-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.